Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population

Heinz Ludwig,Wolfram Pönisch,Stefan Knop,Alexander Egle,Axel Hinke,Martin Schreder,Daniel Lechner,Roman Hájek,Eberhard Gunsilius,Andreas L. Petzer,Katja Weisel,Dietger Niederwieser,Hermann Einsele,Wolfgang Willenbacher,Holger Rumpold,Luděk Pour,Tomas Jelinek,Karl Jochen Krenosz,Angela Meckl,Sandra Nolte,Thomas Melchardt,Richard Greil,Niklas Zojer

Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population

2019

AbstractThis trial evaluated quality of life (QoL) using the EORTC QLQ-C30 and the EORTC QLQ-MY20 instruments in 90 patients with relapsed/refractory multiple myeloma during induction and maintenan...

Keywords:

Diabetes mellitus
Maintenance therapy
Quality of life
Oncology
Immunology
Population
Refractory Multiple Myeloma
Medicine
Ixazomib
Dexamethasone
Thalidomide
Internal medicine
Multiple myeloma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations